Trial Profile
A Phase 3 Study of Velcade (Bortezomib) Dexamethasone (VD) Versus Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) as an Induction Treatment Prior to Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 13 Apr 2016
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone; Thalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 08 Apr 2016 Pooled pharmacogenomics genome-wide association study analysis (n=598) of 3 trials [IFM 2005-01, IFM2007-02, and HOVON-65/GMMG-HD4 ] were published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
- 17 Mar 2012 Planned patient number is 200 according to European Clinical Trials Database record.
- 13 Jun 2010 Interim results presented at the 15th Congress of the European Haematology Association.